TEL AVIV, Israel, August 31, 2010
- ExAblate(R) MR Guided Focused Ultrasound System is Being Used for theFirst Time for Non-invasive Treatment of Prostate Cancer
- Seven Patients With Prostate Confined Low Risk Cancer Treated inClinical Trials
Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit" "Company") that it'ssubsidiary, InSightec Ltd., the global leader in MR guided focused ultrasoundtechnology and the only company to receive FDA approval for its ExAblate(R)system for treating uterine fibroids, announced today that its ExAblate(R)system has been used for the first time for the treatment of prostate cancerpatients. Seven patients with localized low-risk prostate cancer were treatedworldwide so far. The patients were treated at two leading medical centers:the N.N. Petrov Research Institute of Oncology in Saint Petersburg, Russia,and at the National Cancer Centre at the Singapore General Hospital,Singapore.
Prostate cancer is one of the most commonly diagnosed cancers among men.According to the American Cancer Society 217,730 new cases of prostate cancerwill be diagnosed in the US in 2010; and 900,000 new cases diagnosedglobally, according to the World Health Organization. The annual spending inG7 countries (US, UK, France, Italy, Germany, Spain and Japan) is estimatedat 15 Billion Dollars. Treatment options include prostatectomy (surgicalremoval of the prostate gland), radiation therapy, brachytherapy(implantation of radioactive seeds), and cryotherapy. Ultrasound guided highintensity focused ultrasound (HIFU) has also been used, outside the US, totreat prostate cancer.
The ExAblate system, which has been in clinical use for the treatment ofuterine fibroids globally and bone metastases outside of the US, is an ImageGuided, Non-invasive, Robotic Acoustic Surgery system integrating real timemagnetic resonance imaging to visualize the tumor, surrounding tissue and theenergy delivery path together with high intensity focused ultrasound beamwhich is delivered with millimeter precision to destroy the cancerous tumorwithout damaging surrounding tissue, which is the cause of mostcomplications. The use of real-time 3D MR thermometry provides accurateclosed-loop monitoring of the treatment outcome and ability to adjust thetreatment according to specific patient physiology, in real time.
Dr. Kobi Vortman, President and Chief Executive Officer of InSightec,said: "Unfortunately current treatment alternatives are accompanied byrelatively high levels of adverse events which significantly impact thequality of life of prostate cancer patients. The most common are incontinenceand impotence. Due to the introduction of PSA screening tests, prostatecancer is diagnosed at an earlier age thereby increasing the necessity for atreatment option that minimizes adverse events. The ExAblate prostate systemhas been designed to provide effective treatments while minimizing thedebilitating side-effects caused by damage to functional areas of theprostate and neurovascular bundles, thus the system is expected to enablepatients to return to normal life within a day or two while maintaining theirquality of life."
InSightec Ltd. is a privately-held company owned by Elbit Imaging,General Electric, MediTech Advisors, LLC and employees. It was founded in1999 to develop the breakthrough MR guided Focused Ultrasound technology andtransform it into the next generation operating room. Headquartered nearHaifa, Israel, the company has over 160 employees and has invested more than$130 million in research, development, and clinical investigations. Its U.S.headquarters are located in Dallas, Texas. For more information, please goto: http://www.insightec.com/
ExAblate is an Image Guided, non-invasive, Robotic Acoustic Surgerysystem. The ExAblate system is the first to use the MR guided focusedultrasound technology that combines MRI - to visualize the body anatomy, planthe treatment and monitor treatment outcome in real time - and high intensityfocused ultrasound to thermally ablate tumors inside the body non-invasively.MR thermometry, provided uniquely by the system, allows the physician tocontrol and adjust the treatment in real time to ensure that the targetedtumor is treated and surrounding non targeted tissue is spared. The ExAblatesystem was approved by the U.S. Food and Drug Administration in 2004 as atreatment for symptomatic uterine fibroids. Over 6,000 women have beentreated worldwide to date with excellent results. ExAblate(R) 2000 receivedthe European CE Mark for pain palliation of bone metastases in June 2007 andfor Adenomyosis in June 2010.
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields ofbusiness: (i) Commercial and Entertainment Centers - Initiation,construction, and sale of commercial and entertainment centers and othermixed-use real property projects, predominantly in the retail sector, locatedin Central and Eastern Europe and in India. In certain circumstances anddepending on market conditions, Elbit may operate and manage a commercial andentertainment center prior to its sale; (ii) Hotels - Hotels operation andmanagement, primarily in major European cities; (iii) Image Guided Treatment- Investments in the research and development, production and marketing ofmagnetic resonance imaging guided focused ultrasound treatment equipment;(iv) Residential Projects - Initiation, construction and sale of residentialprojects and other mixed-use real property projects, predominatelyresidential, located primarily in India and in Eastern Europe; (v) FashionApparel - distribution and marketing of fashion apparel and accessories inIsrael; and (vi) Other Activities - (a) venture capital investments; (b)investments in hospitals and farm and dairy plants in India, which are inpreliminary stages; and (c) wholesale trade of home applications in India.
Any forward-looking statements in our releases include statementsregarding the intent, belief or current expectations of Elbit Imaging Ltd.and our management about our business, financial condition, results ofoperations, and its relationship with its employees and the condition of ourproperties. Words such as "believe," "expect," "intend," "estimate" andsimilar expressions are intended to identify forward-looking statements butare not the exclusive means of identifying such statements. Actual resultsmay differ materially from those projected, expressed or implied in theforward-looking statements as a result of various factors including, withoutlimitation, the factors set forth in our filings with the Securities andExchange Commission including, without limitation, Item 3.D of our annualreport on Form 20-F for the fiscal year ended December 31, 2009, under thecaption "Risk Factors." Any forward-looking statements contained in ourreleases speak only as of the date of such release, and we caution existingand prospective investors not to place undue reliance on such statements.Such forward-looking statements do not purport to be predictions of futureevents or circumstances, and therefore, there can be no assurance that anyforward-looking statement contained our releases will prove to be accurate.We undertake no obligation to update or revise any forward-lookingstatements. All subsequent written or oral forward-looking statementsattributable to us or persons acting on our behalf are expressly qualified intheir entirety by the cautionary statements set forth in our filings with theSecurities and Exchange Commission including, without limitation, Item 3.D ofour annual report on Form 20-F for the fiscal year ended December 31, 2009,under the caption "Risk Factors."For Further Information: Company Contact: Dudi Machluf Chief Executive Officer (Co-CEO) Tel: +972-3-608-6024 firstname.lastname@example.org Investor Contact: Mor Dagan Investor Relations Tel: +972-3-516-7620 email@example.com
SOURCE Elbit Imaging Ltd.